| Identification | More | [Name]
Taurodeoxycholic acid sodium salt | [CAS]
1180-95-6 | [Synonyms]
2-[(3ALPHA,12ALPHA-DIHYDROXY-24-OXO-5BETA-CHOLAN-24-YL)-AMINO] ETHANESULFONIC ACID SODIUM SALT
3ALPHA,12ALPHA-DIHYDROXY-5BETA-CHOLAN-24-OIC ACID N-[2-SULFOETHYL]AMIDE SODIUM SALT
5BETA-CHOLANIC ACID-3ALPHA,12ALPHA-DIOL 24-N-(2-SULFOETHYL)-AMIDE SODIUM
5-BETA-CHOLANIC ACID-3-ALPHA, 12-ALPHA-DIOL N-(2-SULPHOETHYL)-AMIDE SODIUM SALT
SODIUM TAURODEOXYCHOLATE
SODIUM TAURODEOXYCHOLATE SODIUM SALT
SODIUM TAURODESOXYCHOLATE SODIUM SALT
TAURODEOXYCHOLIC ACID SODIUM
TAURODEOXYCHOLIC ACID SODIUM SALT
Taurodeoxycholic acid sodium salt hydrate
sodium 2-[[(3alpha,5beta,12alpha)-3,12-dihydroxy-24-oxocholan-24-yl]amino]ethane-1-sulphonate
Ethanesulfonic acid, 2-(3.alpha.,5.beta.,12.alpha.)-3,12-dihydroxy-24-oxocholan-24-ylamino-, monosodium salt
sodium taurodeoxylate
Sodium 2-[[(3a,5b,12a)-3,12-dihydroxy-24-oxocholan-24-yl]amino]ethane-1-sulphonate
SODIUM TAUROUSODEOXYCHOLATE
Cholane, ethanesulfonic acid deriv.
Sodium deoxytaurocholate
Sodium taurodesoxycholate
Taurodeoxycholate sodium
Taurodeoxycholic acid sodium salt hydrate,97% | [EINECS(EC#)]
214-652-0 | [Molecular Formula]
C26H44NNaO6S | [MDL Number]
MFCD00003671 | [Molecular Weight]
521.69 | [MOL File]
1180-95-6.mol |
| Chemical Properties | Back Directory | [Appearance]
white to almost white crystalline powder | [Melting point ]
168 °C (dec.)(lit.)
| [alpha ]
33 º (c=3, water) | [storage temp. ]
Freezer (-20°C) | [solubility ]
H2O: 0.5 M at 20 °C, clear, colorless to faintly yellow
| [form ]
Solid | [pka]
1.9 | [color ]
White to Off-White | [Water Solubility ]
soluble | [InChIKey]
YXHRQQJFKOHLAP-UROAIUCXNA-M | [SMILES]
[Na+].[S](=O)(=O)([O-])OCCNC(=O)CCC(C1C2(C(C3C(C4(C(CC3O)CC(CC4)O)C)CC2)CC1)C)C | [CAS DataBase Reference]
1180-95-6(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R37:Irritating to the respiratory system. | [Safety Statements ]
24/25 | [WGK Germany ]
3
| [F ]
3-10 | [HS Code ]
29242990 | [Storage Class]
11 - Combustible Solids |
| Hazard Information | Back Directory | [Chemical Properties]
white to almost white crystalline powder | [Uses]
Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. | [in vivo]
Taurodeoxycholate (1.25-5 mg/kg, p.o., 6 days) sodium salt ameliorates dextran sodium sulfate (DSS)-induced colitis in mice[9].
Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 50 mg/kg; i.p.; once daliy for 34 d) prevents neuropathology and associated behavioral deficits in the 3-nitropropionic acid rat model of Huntington's disease (HD) [10].
Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 500 mg/kg; s.c.; once every 3 d for 7 weeks) leads to a significant reduction in striatal neuropathology of the R6/2 transgenic HD mouse[11].
Taurodeoxycholate (0.5 mg/kg; i.v., once) sodium salt confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis[12].
| Animal Model: | A mouse colitis model (fed with 3% (w/v) DSS in drinking water for the first seven days and then switched to normal drinking water for an additional two days)[9] | | Dosage: | 1.25, 2.5, and 5 mg/kg | | Administration: | Oral gavage (p.o.), from day 3 to day 8, once a day | | Result: | Prevented loss of body weight, shortening of the colon, production of pro-inflammatory cytokines, infiltration of pro-inflammatory cells, and mucosal ulceration in the colon.
|
| Animal Model: | Huntington's disease model in mouse[10] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection; once daliy for 34 d, injected 3-NP at 6 hr after Taurodeoxycholic acid treatment | | Result: | Reduced striatal atrophy, decreased striatal apoptosis, as well as fewer and smaller size ubiquitinated neuronal intranuclear huntingtin inclusions.
Significantly improved locomotor and sensorimotor deficits.
|
| Animal Model: | C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis[12] | | Dosage: | 0.5 mg/kg | | Administration: | Intravenous injection, 30 min or 24 h after LPS injection | | Result: | Improved the survival rate of mice with sepsis.
Decreased liver and kidney damage in septic mice.
Ameliorated systemic inflammation and normalized blood pressure in septic mice.
|
| [Purification Methods]
The Na salt is dissolved in the smallest volume of H2O, a saturated solution of aqueous NaCl/Et2O is added and the mixture is stored at 0o for 24hours. Then shake the mixture well, keep it in the cold for another day and filter the crystals with gentle shaking, wash them with ice-cold saturated aqueous NaCl saturated with Et2O, dry them over CaCl2 and extract them with absolute EtOH. Add ~10mL of H2O to the solid followed by enough Et2O to incipient cloudiness. Store it overnight at 0o. Add ice-cold Et2O to make 250mL, collect the crystals, wash them with Et2O then pet ether and dry them in air. The purification can be repeated with NaCl and Et2O with ~85% recovery. NB: precipitation will not occur unless enough H2O is present. Its solubility in H2O is 10%. [Cortese J Am Chem Soc 59 2532 1937.] The free acid has m 141-144o. [Norman Ark Kemi 8 331 1956.] It forms mixed micelles and solubilises some membrane proteins [Hajjar et al. J Biol Chem 2 5 8 192 1983]. [Beilstein 10 IV 1611.] |
|
|